Valuation
- Market cap
- 12,405,000
- Revenue TTM
- $1,880,000
- Net income TTM
- $-38,650,000
- P/E (trailing)
- 0.00
- P/E (forward)
- —
- Profit margin
- -2,055.85%
- Debt to equity
- 0.00
Trading
- Volume
- 22,100
- Avg volume
- 54,390
- Day's range
- $0.74 – $0.78
- Shares out
- 15,703,000
- Stochastic %K
- 7%
- Beta
- 2.07
- Analysts
- Strong Buy
- Price target
- $17.08
Company profile
Radiopharm Theranostics Limited a clinical-stage radiotherapeutics company, engages in the development of radiopharmaceutical products for diagnostic and therapeutic uses in areas with high unmet medical needs in the United States. The company develops RAD101, a pivalate brain metastasis diagnostic; RAD102, a pivalate therapeutic; RAD201a, a Nano-mAb HER-2 breast diagnostic; RAD202, a Nano-mAb HER-2 breast therapeuti...
Show more
Radiopharm Theranostics Limited a clinical-stage radiotherapeutics company, engages in the development of radiopharmaceutical products for diagnostic and therapeutic uses in areas with high unmet medical needs in the United States. The company develops RAD101, a pivalate brain metastasis diagnostic; RAD102, a pivalate therapeutic; RAD201a, a Nano-mAb HER-2 breast diagnostic; RAD202, a Nano-mAb HER-2 breast therapeutic; RAD203, a Nano-mAb PDL1 non-small cell lung diagnostic; and RAD204, a Nano-mAb PDL1 non-small cell lung therapeutic. It is also developing RAD301 and RAD302, which are Avß6-Integrin pancreatic diagnostic and therapeutic products; RAD401, a PSA-mAb prostate cancer diagnostic; and RAD402, a PSA-mAb prostate cancer therapeutic. The company was incorporated in 2021 and is based in Carlton, Australia.
- Industry
- Biotechnology
- Sector
- Healthcare
- Phone
- 61 3 9824 5254
- Website
- https://www.radiopharmtheranostics.com
- Address
- 62 Lygon Street, Level 3, Carlton, Australia
Latest news
No headlines yet.
